Syremis Therapeutics secures $165M Series A funding co-led by Dexcel Pharma and Third Rock Ventures to develop innovative medicines for mental health.
Amount Raised
$165 Million
Round Type
Series A
Tel AvivBiotechnologyHealth CareInvestors
Description
Syremis Therapeutics has launched with a $165 million financing to develop treatments for mental health conditions. The Series A funding will support the advancement of their clinical pipeline. Syremis' lead program is currently in Phase 1 for schizophrenia and is designed to potentially offer better treatment options. This financing aims to address a significant unmet need in mental health care.
Quick answer
Syremis Therapeutics raised $165 Million in a Series A round, dated December 18, 2025. Investors: Third Rock Ventures, Bain Capital Life Sciences, GV, Qvt, Pictet and Dexcel Pharma. Syremis Therapeutics is based in Tel Aviv, Tel Aviv District, Israel.
- How much did Syremis Therapeutics raise?
- Syremis Therapeutics raised $165 Million in a Series A round on December 18, 2025.
- Who invested in Syremis Therapeutics?
- Third Rock Ventures, Bain Capital Life Sciences, GV, Qvt, Pictet and Dexcel Pharma are named as investors in this round.
- What does Syremis Therapeutics do?
- Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health.
- Where is Syremis Therapeutics based and how big is it?
- Syremis Therapeutics is based in Tel Aviv, Tel Aviv District, Israel. Fundz records about 18 employees.
- Who are the decision-makers at Syremis Therapeutics?
- Fundz holds 1 contact at Syremis Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Syremis Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- ORamaVR raised $4.5M (Seed) on January 30, 2026.
- CytoDyn raised $19M on January 30, 2026.
- Richtech Robotics raised $39M (Post-IPO Equity) on January 29, 2026.
- Biopeak raised $2.7M (Seed) on January 29, 2026.
- Tenpoint Therapeutics raised $235M (Series B) on January 29, 2026.
- PranaX raised $17M (Series A) on January 29, 2026.
Who to call at Syremis Therapeutics, and when
A new round usually means Syremis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Syremis Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Syremis Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Syremis Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Syremis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSyremis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.